Questioning the importance of LDL cholesterol: Don't throw the baby out with the bathwater!

Cardiovascular Journal of Africa

Volumn 19, Issue 2, 2008, Pages 63-64

  Raal, F J ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EDITORIAL; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; PATHOGENESIS; PREVALENCE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERLIPIDEMIAS; RISK FACTORS; TREATMENT OUTCOME;

EID: 45349101577     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Kastelein JP, Sager PT, de Groot E, Veltri E. Comparison of ezetimibe plus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolaemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 2005; 149: 234-239.
2. Carey J. Do cholesterol drugs do any good? Business Week 2008; January 28: 52-59.
3. Taubes G. What's cholesterol got to do with it? New York Times 2008; January 27: 18.
4. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomised control trial. J Am Med Assoc 2004; 291: 1071-1080.
5. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. J Am Med Assoc 2006; 295: 1556-1565.
6. O'Keefe JH, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl. J Am Coll Cardiol 2004; 43: 2142-2146.
7. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-1272.
8. Grundy SM. Is lowering low-density lipoprotein an effective strategy to reduce cardiac risk? Circulation 2008; 117: 569-573.
9. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
10. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes undergoing haemodialysis. N Engl J Med 2005; 353: 238-248.
11. Knopp RH, d' Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular endpoints in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart disease Endpoints in Non-insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 2006; 29: 1478-1485.
12. Kjekhus J, Apetrei E, Barrios V, for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
13. Rader DJ. Illuminating HDL - is it still a viable therapeutic target? N Engl J Med 2007; 357: 2180-2183.
14. Brown MS, Goldstein JS. Heart attacks - gone with the century? Science 1996; 272: 629.
15. Armitage J. The safety of statins in clinical practice, Lancet 2007; 370: 1781-1790.
16. Steinberg D. The Cholesterol Wars: The Cholesterol Sceptics vs the Preponderance of Evidence. New York: Academic Press, 2007. ISBN 978-0123739797.